Pain Cloud®

Identifying the optimal patient group for clinical trials is a vital step in analgesic drug development. 🔬 Historically this has been a key issue which has proved exceptionally difficult in pain, accounting for the highest R&D costs and the lowest clinical development success rates compared to other therapeutic areas. 🔬 Creating new methodology to improve this is critical to help move research into novel medicines for millions of patients suffering with chronic pain. Pain Cloud®, a B2B platform created by eptivA Therapeutics Ltd. and Infopoly, uses the first #precisionmedicine approach to #pain, creating more effective treatments, increasing clinical success and reducing costs. Our Personalized Analgesics® #bioinformatic approach creates thousands of nodes of data via novel human-focused #networkbiology, with the Pain Landscape highlighting over 1,000 conditions associated with chronic pain. Our approach is centered around inclusive research, allowing those developing new analgesics to identify optimal patient populations or stratified groups to develop precise analgesics.

In part one of this series, we delved into how open-source data sets, although vastly underutilized, present an untapped resource that could potentially shift how we approach pain research and development. In this part two, we will explore how the explosion of biomedical data will require complex integration and analysis to better understand the molecular basis of phenotypes.

Why does pain research typically only focus on a small number of patient groups? The research is there, yet traditional methods of research still ignore large subpopulations of patients, missing out on unique revenue streams and, more importantly, creating a brighter future for pain treatment. In this article, we share why research is limited, how to work towards analgesic innovation and how Pain Cloud® can help you access a database of 1,000s of pain conditions and improve the clinical success rate of your new drugs. #PainCloud #PainResearch #TargetValidation #PainManagement

Drug repurposing presents a number of benefits for businesses producing analgesics and pain patients alike. Find out more in this article: https://lnkd.in/ejyKTn_n #PainMedicine #DrugRepurposing #Analgesics #PatientSafety

With 80% of healthcare data unstructured, it is clear that our industry needs a new approach to research that prioritizes efficiency, clarity and, importantly, success. In pain R&D, open-source data is routinely underused, with institutions focusing on traditional proprietary methods. In this article, we share the advantages of using open-source databases, whether for collaboration or proprietary means, and explain how Pain Cloud® can help make it happen. #OpenSourceData #PainResearch #MedicalResearch #Medicine

What’s the problem with standard pain R&D? Pain does not discriminate, so focusing only on a limited number of diseases with regulatory pathway effectively excludes millions of patients, exhibiting different experiences and symptoms, from the research process. The limited number of patient groups used in industry are complex, so patient stratification is required to make target validation more accurate. Identifying the optimal pain group is crucial in aiming for the highest probability of success. But, in the pain area, this has proven exceptionally difficult due to limited target validation technologies. #PainMedicine #Analgesics #PatientStratification #ClinicalDevelopment

Research published by JAMA Network Health Systems & Recruitment in June found that the estimated mean cost of developing a new drug was around $172.7 million. They looked across different therapeutic areas and found there was a significant difference between them with the lowest being $72.5 million for genitourinary to the most expensive $297.1 million for pain and anaesthetics. These figures include post-marketing studies – but they don’t include the cost of failure. When you add the cost of drugs failing in development, the average figure becomes $515.8 million and once again pain and anaesthetics is the most expensive therapeutic area with costs of a staggering $1756.2 million. So what's the solution to this? Pain Cloud®'s Personalized Analgesics® bioinformatic approach creates thousands of nodes of data via novel human-focused network biology, all linked to our proprietary Pain Landscape® database of thousands of diseases. By using Pain Cloud’s technology, analgesic development will be quicker, less expensive, and more successful. It is hoped that safer, more efficacious, and more targeted pain medications, utilizing insights from Pain Cloud, will become available to those who need it most in the next few years. This approach, which prioritizes speed, efficiency and accuracy, will start a positive chain reaction, resulting in further efficiency across every stage of analgesic development. Read more about Pain Cloud: https://paincloud.ai/ #PainResearch #PersonalizedAnalgesics #Analgesics #Anaesthetics

Is personalized medicine the future of analgesics? Personalized pain treatment can have a huge impact on the research and development of analgesics – and the strategies learned from it will completely revolutionize pharmaceuticals. Read our recent article to find out more about how personalized medicine is changing the way patients are treated. #PersonalizedMedicine #PainTreatment #ChronicPain #Pharmaceuticals

By using Pain Cloud®’s technology, automated by Infopoly, pain research and development can become quicker, less expensive and, importantly, more successful. Here’s what Mark J. Field, CEO and Co-Founder of eptivA Therapeutics Ltd. and Pain Cloud has to say: “By using Pain Cloud®, researchers can solve the cost-intensive traditional R&D with a streamlined process to precisely match targets and mechanisms to specific patient groups that saves time and reduces spending." Discover how Pain Cloud® can benefit your company: https://lnkd.in/edNq6qXt #PainMedicine #Therapeutics #PainResearch #Analgesics #TargetValidation

We are delighted to announce our new partnership with Dr Matt Parker and University of Surrey aimed at advancing the development of chronic pain medicines. Dr Parker has recently been awarded a Short Industry Fellowship from the #RoyalSociety to work with eptivA Therapeutics Ltd. researching a new personalised medication for those suffering from chronic pain. During this partnership, Surrey scientists, in collaboration with eptivA, will examine the effectiveness of cholecalciferol as a non-opioid pain reliever. This builds on findings from eptivA, which used its Pain Cloud® research platform to uncover links between the Vitamin D receptor gene and specific pain conditions. EptivA employs a data-driven, personalised approach to pain management. Central to this research partnership is their innovative new Pain Cloud® platform, developed in collaboration with biotech firm Infopoly. This platform uses in silico modelling to validate new targets for pain research and, crucially, identify the most suitable patient groups for clinical development. Link to full press release: https://lnkd.in/eRNfXJ7W